Get the Stockscreener App
5.62
0.36%
0.02
After Hours:
5.49
-0.13
-2.31%
Nutriband Inc stock is traded at $5.62, with a volume of 19,539.
It is up +0.36% in the last 24 hours and up +11.73% over the past month.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
See More
Previous Close:
$5.60
Open:
$5.84
24h Volume:
19,539
Relative Volume:
0.39
Market Cap:
$62.66M
Revenue:
$2.09M
Net Income/Loss:
$-5.28M
P/E Ratio:
-8.3881
EPS:
-0.67
Net Cash Flow:
$-3.64M
1W Performance:
-1.75%
1M Performance:
+11.73%
6M Performance:
+18.82%
1Y Performance:
+19.07%
1-Day Range:
$5.54
$5.84
1-Week Range:
$5.54
$6.00
52-Week Range:
$3.7223
$11.78
Nutriband Inc Stock (NTRB) Company Profile
Name
Nutriband Inc
Sector
Industry
Phone
407 377-6695
Address
121 S. ORANGE AVE., ORLANDO
Compare NTRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTRB
Nutriband Inc
|
5.62 | 63.80M | 2.09M | -5.28M | -3.64M | -0.67 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Nutriband Inc Stock (NTRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-25 | Initiated | Noble Capital Markets | Outperform |
Nutriband Inc Stock (NTRB) Latest News
Nutriband (NASDAQ: NTRB) Strengthens Pharma Footprint Through Key Alliances - The Globe and Mail
Nutriband Expands Market Presence Through Strategic Health Industry Partnerships - citybuzz -
Nutriband (NASDAQ: NTRB) Pioneers Innovative Approach to Opioid Crisis with Game-Changing Transdermal Patch - The Globe and Mail
Nutriband Develops Innovative Abuse-Deterrent Fentanyl Patch Amid Opioid Crisis Regulatory Changes - citybuzz -
Nutriband (NASDAQ: NTRB) Innovating Abuse-Deterrent Drug Delivery in a Shifting Opioid Landscape - The Globe and Mail
Nutriband Inc. Quarterly Report Highlights Strong Cash Position, and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025 - ACCESS Newswire
(NTRB) Trading Report - news.stocktradersdaily.com
Nutriband Inc. to Ring NASDAQ Stock Market Opening Bell on December 3, 2021 - ACCESS Newswire
Nutriband (NASDAQ: NTRB) CEO Issues Shareholder Letter Highlighting Milestones, Commercialization Goals - Barchart.com
Examining Nutriband Inc (NTRB) more closely is necessary - uspostnews.com
A Tale of Resilience: Nutriband Inc Amid Stock Market Turbulence - investchronicle.com
Nutriband CEO Publishes Letter to Shareholders - GlobeNewswire
Nutriband (NASDAQ: NTRB) Leadership Team: Driving Innovation and Shaping the Future of Global Healthcare - The Globe and Mail
Nutriband (NTRB) Highlights Key Milestones and Future Goals Amid - GuruFocus
Nutriband Inc. (NASDAQ: NTRB) Solution To Fentanyl Abuse Could Translate To $200 Million In Peak Revenue - marketscreener.com
Nutriband CEO Publishes Letter to Shareholders | NTRB Stock News - GuruFocus
Nutriband projects strong sales for abuse-deterrent patches - Investing.com Australia
ForexTV | Small Business Resources - ForexTV
Nutriband Full Year 2025 Earnings: Misses Expectations - Yahoo Finance
Nutriband Inc reports results for the quarter ended January 31Earnings Summary - TradingView
NutriBand Inc. SEC 10-K Report - TradingView
Press Release Distribution & PR Platform - ACCESS Newswire
Should You Buy, Sell or Hold Amazon Stock Before Q1 Earnings? - The Globe and Mail
Why Nutriband (NASDAQ: NTRB) Is ‘One to Watch’ - The Globe and Mail
Big Oil Could Trim Buybacks After Price Rout - The Globe and Mail
Why Nutriband (NASDAQ: NTRB) Is ‘One To Watch’ - Barchart.com
Nutriband Inc. Provides Update on Seven-for-Six Forward Stock Split - ACCESS Newswire
Nutriband Inc. Initiates Plans to Offer Topical Lotion Contract Manufacturing Services - ACCESS Newswire
Nutriband Closes $8.4M Private Placement for Commercial Development of Aversa(R) Fentanyl Transdermal Patch Through FDA Submission - ACCESS Newswire
Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30th through February 1st - ACCESS Newswire
Nutriband Inc. Announces $8.4M Private Placement - ACCESS Newswire
Is Disney Stock a Buy Now as Trump Tones Down Trade War Rhetoric? - The Globe and Mail
Nutriband (NASDAQ: NTRB): Building A Moat Around Abuse-Deterrent Drug Delivery - Barchart.com
(NTRB) Investment Report - news.stocktradersdaily.com
Nutriband (NASDAQ: NTRB): Building a Moat Around Abuse-Deterrent Drug Delivery - The Globe and Mail
Nutriband Strengthens Intellectual Property Portfolio for Abuse-Deterrent Drug Delivery - citybuzz -
Stocks in play: BioVaxys Technology Corp - The Globe and Mail
Nutriband (NASDAQ: NTRB) CEO Named EY Entrepreneur of the Year 2025 Finalist - The Globe and Mail
Nutriband (NASDAQ: NTRB) Is ‘One to Watch’ - The Globe and Mail
Nutriband (NASDAQ: NTRB) Is ‘One To Watch’ - Barchart.com
Nutriband Advances Opioid Safety with Innovative AVERSA Technology - citybuzz -
Nutriband (NTRB) Achieves Key Patent Approval in Macao for AVERS - GuruFocus
Nutriband Granted Patent in Macao for its AVERSA Abuse Deterrent Transdermal Technology | NTRB Stock News - GuruFocus
Nutriband Granted Patent in Macao for its AVERSA Abuse Deterrent Transdermal Technology - GlobeNewswire
Nutriband secures Macao patent for drug abuse deterrent tech By Investing.com - Investing.com South Africa
Nutriband Receives Patent for Abuse, Misuse Deterrent Transdermal Systems in Macao - marketscreener.com
Nutriband Inc Stock (NTRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):